• Lantheus Holdings has completed the sale of its SPECT business unit and reported progress in neurodegenerative imaging, including past CTAD 2025 data presentations and anticipated 2026 regulatory decisions for new beta-amyloid and tau agents, while planning a reformulated Pylarify launch to address pricing pressures.
• This repositioning concentrates capital and management attention on higher-growth imaging platforms, potentially altering how investors view the balance between product concentration risk and the company’s innovation pipeline.
• Next, we’ll examine how the SPECT divestiture and renewed neurodegenerative imaging focus reshape Lantheus’s existing investment narrative and risk balance.

We've found 11 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Lantheus Holdings Investment Narrative Recap

To own Lantheus today, you need to be comfortable with a focused radiopharmaceutical business where earnings strength and a solid balance sheet underpin the case, while pricing pressure and product concentration remain central risks. The SPECT divestiture and neurodegenerative imaging progress do not materially change the near term catalyst, which is the expected March 2026 approval of the reformulated Pylarify, nor the biggest current risk around ongoing PSMA PET price compression and potential flat growth.

The most relevant recent development is the confirmation of Pylarify’s reformulated product and its expected March 2026 approval, which sits at the heart of the short term thesis. If this higher yield formulation gains traction, it could influence how the market views Lantheus’s ability to stabilize prostate cancer imaging economics and gradually rebalance away from over reliance on legacy Pylarify contracts.

Yet despite this progress, investors should be aware of the continuing risk that aggressive PSMA PET pricing pressure could...

Lantheus Holdings' narrative projects $1.8 billion revenue and $419.8 million earnings by 2028. This requires 5.7% yearly revenue growth and about a $148.8 million earnings increase from $271.0 million today.

Uncover how Lantheus Holdings' forecasts yield a $82.29 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Seven fair value estimates from the Simply Wall St Community span a wide range, from about US$64 to more than US$158 per share, underscoring how far apart individual views can be. When you set those against the current focus on reformulated Pylarify as a key earnings catalyst, it highlights why it can be useful to compare several independent perspectives before forming a view on Lantheus’s potential path from here.

Explore 7 other fair value estimates on Lantheus Holdings - why the stock might be worth 6% less than the current price!

Build Your Own Lantheus Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Lantheus Holdings research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Lantheus Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lantheus Holdings' overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Find companies with promising cash flow potential yet trading below their fair value.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.